Among them are the combinations of: Ipilimumab (αCTLA-4) with DBF/TRM evaluated for V600E/K mutation positive metastatic or unresectable melanoma patients (NCT01767454) in an ongoing phase I study 34; pembrolizumab (αPD-1 therapy) with DBF/TRM, in an ongoing phase I/II study, (NCT02130466) 35; and a phase III, advanced clinical trial testing atezolizumab (αPD-L1) with vemurafenib/cobimetinib as a first-line treatment in BRAF V600 mutation-positive patients with unresectable advanced melanoma (NCT02908672) 36. This evidence concerns the gene BRAF and melanoma.